Home › Funds › JANUS INVESTMENT FUND › Janus Henderson Global Life Sciences Fund
Fund family: JANUS INVESTMENT FUND · Filed by JANUS INVESTMENT FUND (CIK 277751) · SEC series S000010494
Share classes and tickers: JAGLX (C000028956), JFNAX (C000077752), JFNCX (C000077753), JFNIX (C000077754), JFNNX (C000198286), JFNSX (C000077755), JNGLX (C000083538)
“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 780 with, 21 against, 0 abstentions (not counted as with management). Shareholder proposals: 10 FOR, 11 AGAINST, 0 abstained, by the filing’s own vote-source field.
The same two figures as JANUS INVESTMENT FUND’s manager page (17,858 ballot items across 30 funds and accounts), counted the same way for this fund.
| 2025-2026 | This fund | Items | JANUS INVESTMENT FUND | Items |
|---|---|---|---|---|
| Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters) | 98.8% | 745 | 97.2% | 15,061 |
| Backed environmental and social shareholder proposals at US companies | n/a | 8 | 3.6% | 392 |
Each ballot item this fund voted is set against the votes of the other JANUS INVESTMENT FUND funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.
Voted differently from most JANUS INVESTMENT FUND funds on 6 items (2.0% of the 305 items where a comparison was possible).
| Company | Meeting | Item | This fund | Most JANUS INVESTMENT FUND funds | Mgmt | Result |
|---|---|---|---|---|---|---|
| Danaher Corporation | 2026-05-05 | To elect the eleven directors named in the attached Proxy Statement to hold office until the 2027 Annual Meeting of Shareholders and until their successors are elected and qualified: A. Shane Sanders | Against | FOR — 5 of 5 JANUS INVESTMENT FUND funds | Against | Elected, 73.8% support |
| Danaher Corporation | 2026-05-05 | To elect the eleven directors named in the attached Proxy Statement to hold office until the 2027 Annual Meeting of Shareholders and until their successors are elected and qualified: Raymond C. Stevens, Ph.D. | Against | FOR — 5 of 5 JANUS INVESTMENT FUND funds | Against | Elected, 79.7% support |
| Danaher Corporation | 2026-05-05 | To elect the eleven directors named in the attached Proxy Statement to hold office until the 2027 Annual Meeting of Shareholders and until their successors are elected and qualified: Teri L. List | Against | FOR — 5 of 5 JANUS INVESTMENT FUND funds | Against | Elected, 77.7% support |
| HCA Healthcare, Inc. | 2026-04-23 | Shareholder Stockholder proposal, if properly presented at the meeting, regarding stockholders' right to act by written consent. | For | AGAINST — 3 of 3 JANUS INVESTMENT FUND funds | Against | Not approved, 22.0% support |
| Eli Lilly and Company | 2026-05-04 | Shareholder Shareholder proposal to adopt a policy and amend the bylaws to require an independent board chair. | Against | FOR — 6 of 8 JANUS INVESTMENT FUND funds | For | Not approved, 33.7% support |
| Zoetis Inc. | 2026-05-20 | Shareholder Shareholder proposal to permit shareholder action by written consent. | For | AGAINST — 3 of 4 JANUS INVESTMENT FUND funds | Against | — |
Download all 6 differences (CSV)
The same votes as “with management” above, by the sector of the company voted on. 84.1% of this fund’s 801 such votes could be given a sector; the other 127 (15.9%) are at companies without one and are not in the table.
| Sector | Votes | Against management | Share |
|---|---|---|---|
| Health Care | 630 | 20 | 3.2% |
| Industrials | 27 | 0 | 0.0% |
| Consumer Staples | 17 | 1 | 5.9% |
| Proposal type | Items | Against management |
|---|---|---|
| Director Elections | 512 | 0 |
| Say-on-Pay | 82 | 0 |
| Audit-related | 81 | 0 |
| Compensation | 45 | 1 |
| Corporate Governance | 42 | 12 |
| Capital Structure | 26 | 0 |
| Extraordinary Transactions | 8 | 0 |
| Other Social Issues | 6 | 5 |
| Shareholder Rights and Defenses | 4 | 0 |
| Environment or Climate | 3 | 3 |
Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.
| Company | Meeting | Est. position | Items | Against mgmt |
|---|---|---|---|---|
| Eli Lilly and Company | May 4, 2026 | $702M | 10 | 2 |
| Johnson & Johnson | April 23, 2026 | $432M | 15 | 1 |
| AbbVie Inc. | May 8, 2026 | $272M | 8 | 1 |
| UnitedHealth Group Incorporated | June 1, 2026 | $248M | 12 | 1 |
| Thermo Fisher Scientific Inc. | May 20, 2026 | $181M | 13 | 0 |
| Revolution Medicines, Inc. | June 18, 2026 | $181M | 4 | 0 |
| argenx SE | November 18, 2025 | $167M | 1 | 0 |
| argenx SE | May 6, 2026 | $162M | 12 | 0 |
| Meeting | Company | Proposal | Fund | Mgmt |
|---|---|---|---|---|
| May 4, 2026 | Eli Lilly and Company | Shareholder proposal to adopt a policy and amend the bylaws to require an independent board chair. Shareholder proposal | Against | For |
| May 4, 2026 | Eli Lilly and Company | Shareholder proposal to prepare an annual lobbying report. Shareholder proposal | Against | For |
| April 23, 2026 | Johnson & Johnson | Independent Board Chair Shareholder proposal | For | Against |
| May 8, 2026 | AbbVie Inc. | Stockholder Proposal - to Adopt a Policy to Require an Independent Chair Shareholder proposal | For | Against |
| June 1, 2026 | UnitedHealth Group Incorporated | If properly presented at the 2026 Annual Meeting of Shareholders, the shareholder proposal requesting the adoption of a policy to require any Board Chair to be independent. Shareholder proposal | For | Against |
| May 13, 2026 | Vertex Pharmaceuticals Incorporated | Shareholder proposal, if properly presented at the meeting, regarding shareholder right to act by written consent. Shareholder proposal | Against | For |
| May 19, 2026 | Amgen Inc. | Stockholder proposal to require an independent board chairman. Shareholder proposal | For | Against |
| April 23, 2026 | HCA Healthcare, Inc. | Stockholder proposal, if properly presented at the meeting, regarding a report on healthcare consequences. Shareholder proposal | Against | For |
| April 23, 2026 | HCA Healthcare, Inc. | Stockholder proposal, if properly presented at the meeting, regarding stockholders' right to act by written consent. Shareholder proposal | For | Against |
| May 14, 2026 | CVS Health Corporation | Stockholder Proposal for Reducing the Threshold for Our Stockholder Right to Act By Written Consent. Shareholder proposal | Against | For |
| May 26, 2026 | Merck & Co., Inc. | Shareholder proposal regarding a report on DEI risks in federal contracting. Shareholder proposal | Against | For |
| May 26, 2026 | Merck & Co., Inc. | Shareholder proposal regarding a report on healthcare coverage gaps. Shareholder proposal | Against | For |
Meetings with a proxy contest or competing nominees (1 in 2025-2026), and how the fund voted the items on its ballot.
809 ballot items at 87 meetings in 2025-2026. Download all votes (CSV)
Recent votes against management’s recommendation at large companies.
In the 2025-2026 proxy season, Janus Henderson Global Life Sciences Fund (JAGLX) voted at 87 shareholder meetings of 83 companies, on 809 ballot items in all. Where management made a recommendation, the fund followed it on 97.4% of the items and voted against it 21 times. Its most frequent area of disagreement was corporate governance (12 of its votes against management). It voted on 21 shareholder proposals. It voted FOR the board's own proposals more often than JANUS INVESTMENT FUND's funds as a whole (98.8% against 97.2%). It voted differently from most JANUS INVESTMENT FUND funds on 6 items. 1 of its meetings was contested.
Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of JANUS INVESTMENT FUND’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.